Datamonitor Healthcare CNS Disease Analysis: Schizophrenia

July 12, 2021

The current dynamics of the antipsychotic market show domination by atypical antipsychotics, typically oral agents, but there is also increasing uptake of long-acting injectable (LAI) neuroleptics, which will continue. Oral atypical antipsychotics that were historical blockbusters are now facing intense generic erosion. The highest-selling oral antipsychotic is Latuda, one of the newer atypical drugs, but its market exclusivity is only set to last until 2023. 

This Datamonitor Healthcare report contains a Disease Analysis module.

Indications Covered:

Schizophrenia